Evidence map›Paper›PMID 41041628›Full record

ReviewJTO clinical and research reports2025

What Is On the Horizon for the Diagnosis and Treatment of SCLC and Large Cell Neuroendocrine Cancer?

Sun Min Lim, Joo Sung Gabriel Shim, Hyo Sup Shim, Junko Tanizaki, Jorn Nutzinger, Byoung Chul Cho, Ross A Soo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sun Min LimDivision of Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Joo Sung Gabriel ShimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Hyo Sup ShimDepartment of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Junko TanizakiDepartment of Medical Oncology, Kindai University, Faculty of Medicine, Osaka, Japan.
Jorn NutzingerDepartment of Haematology-Oncology, National University Cancer Institute, Singapore.
Byoung Chul ChoDivision of Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Ross A SooDepartment of Haematology-Oncology, National University Cancer Institute, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SCLC is a high-grade neuroendocrine malignancy associated with poor prognosis, comprising 15% of lung cancer cases globally. Advances in genetic profiling have revealed that SCLC is a molecularly heterogeneous disease, categorized into subtypes such as SCLC-A, SCLC-N, SCLC-P, and SCLC-I, on the basis of their neuroendocrine and immune-related characteristics. This heterogeneity underscores the need for tailored therapeutic strategies. Large cell neuroendocrine carcinoma (LCNEC) shares histologic and molecular similarities with SCLC but remains a distinct entity. LCNEC is categorized into two major subtypes: Type I, characterized by

Indexed as

DiagnosticsLarge cell neuroendocrine carcinomaNovel therapiesSmall cell lung cancer

Identifiers

PMID41041628
PMCPMC12485632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.